PMID- 35892878
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230308
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 15
DP  - 2022 Jul 25
TI  - A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic 
      Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular 
      Carcinoma Accompanied by Portal Vein Tumor Thrombus.
LID - 10.3390/cancers14153619 [doi]
LID - 3619
AB  - Background: This study compared the effectiveness of the combined administration 
      of sorafenib, an immune checkpoint inhibitor, transcatheter arterial 
      chemoembolization (TACE), and stereotactic body radiation therapy (SBRT) (SITS 
      group) vs. sorafenib combined with TACE (ST group) in treating and downstaging 
      advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). 
      Methods: The present study included patients with advanced HCC and PVTT treated 
      with one of the above combination therapies. The downstaging rate, objective 
      response rate (ORR), progression-free survival (PFS), overall survival (OS), 
      disease control rate (DCR), and adverse events (AEs) were assessed. Results: 
      Sixty-two patients were analyzed. The ORR was elevated in the SITS group compared 
      with the ST group (p = 0.036), but no differences were found in DCR (p = 0.067). 
      The survival analysis revealed higher PFS (p = 0.015) and OS (p = 0.013) in the 
      SITS group, with median PFS and OS times of 10.4 and 13.8 months, respectively. 
      Ten patients displayed successful downstaging and underwent surgery in the SITS 
      group, vs. none in the ST group. The prognosis was better in surgically treated 
      patients compared with the non-surgery subgroup, based on PFS (p < 0.001) and OS 
      (p = 0.003). Despite a markedly higher rate of AEs in the SITS group (p = 0.020), 
      including two severe AEs, the SITS combination therapy had an acceptable safety 
      profile. Conclusion: The SITS combination therapy yields higher PFS and OS than 
      the combined administration of sorafenib and TACE in patients with advanced HCC 
      and PVTT, especially as a downstaging strategy before surgery.
FAU - Zhang, Zeyu
AU  - Zhang Z
AD  - Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, 
      Changsha 410078, China.
FAU - Li, Chan
AU  - Li C
AUID- ORCID: 0000-0002-0232-8603
AD  - Department of Cardiovascular Medicine, Xiangya Hospital, Central South 
      University, Changsha 410078, China.
FAU - Liao, Weijun
AU  - Liao W
AD  - Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, 
      Changsha 410078, China.
FAU - Huang, Yun
AU  - Huang Y
AD  - Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, 
      Changsha 410078, China.
FAU - Wang, Zhiming
AU  - Wang Z
AD  - Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, 
      Changsha 410078, China.
LA  - eng
GR  - CXPJJH1200008-07/Hubei Chen Xiaoping science and Technology Development 
      Foundation/
PT  - Journal Article
DEP - 20220725
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9332229
OTO - NOTNLM
OT  - downstaging
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitor
OT  - sorafenib
OT  - stereotactic body radiation therapy
OT  - transcatheter arterial chemoembolization
COIS- The authors declare no competing interests.
EDAT- 2022/07/28 06:00
MHDA- 2022/07/28 06:01
PMCR- 2022/07/25
CRDT- 2022/07/27 04:56
PHST- 2022/06/09 00:00 [received]
PHST- 2022/07/16 00:00 [revised]
PHST- 2022/07/19 00:00 [accepted]
PHST- 2022/07/27 04:56 [entrez]
PHST- 2022/07/28 06:00 [pubmed]
PHST- 2022/07/28 06:01 [medline]
PHST- 2022/07/25 00:00 [pmc-release]
AID - cancers14153619 [pii]
AID - cancers-14-03619 [pii]
AID - 10.3390/cancers14153619 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Jul 25;14(15):3619. doi: 10.3390/cancers14153619.